Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells $250,700.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the business’s stock in a transaction dated Tuesday, March 24th. The stock was sold at an average price of $100.28, for a total value of $250,700.00. Following the completion of the transaction, the chief executive officer owned 2,232,500 shares in the company, valued at approximately $223,875,100. This trade represents a 0.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

iRadimed Stock Performance

Shares of IRMD opened at $97.36 on Friday. iRadimed Corporation has a one year low of $47.48 and a one year high of $107.90. The stock has a 50-day moving average price of $100.37 and a 200 day moving average price of $90.46. The company has a market capitalization of $1.24 billion, a P/E ratio of 55.63 and a beta of 1.12.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The company had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities research analysts forecast that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. This is a boost from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date was Monday, February 23rd. iRadimed’s payout ratio is presently 45.71%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on IRMD shares. Lake Street Capital reiterated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Finally, Roth Mkm restated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

Institutional Investors Weigh In On iRadimed

Institutional investors have recently made changes to their positions in the company. Hsbc Holdings PLC raised its position in shares of iRadimed by 19.2% during the 4th quarter. Hsbc Holdings PLC now owns 21,559 shares of the medical equipment provider’s stock valued at $2,103,000 after acquiring an additional 3,468 shares in the last quarter. Aristides Capital LLC boosted its holdings in iRadimed by 5.0% in the fourth quarter. Aristides Capital LLC now owns 27,734 shares of the medical equipment provider’s stock worth $2,698,000 after purchasing an additional 1,309 shares during the period. T. Rowe Price Investment Management Inc. boosted its holdings in iRadimed by 410.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after purchasing an additional 205,783 shares during the period. Invesco Ltd. increased its stake in iRadimed by 473.9% during the fourth quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock valued at $3,418,000 after purchasing an additional 29,010 shares during the last quarter. Finally, NewEdge Advisors LLC bought a new stake in iRadimed during the fourth quarter valued at $1,679,000. 92.34% of the stock is currently owned by institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.